Tectonic Therapeutic, Inc. (TECX)
| Market Cap | 512.60M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -74.15M |
| Shares Out | 18.78M |
| EPS (ttm) | -4.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 167,830 |
| Open | 29.03 |
| Previous Close | 28.75 |
| Day's Range | 26.61 - 29.03 |
| 52-Week Range | 14.39 - 36.03 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 75.20 (+175.46%) |
| Earnings Date | May 7, 2026 |
About TECX
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company’s lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPC... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for TECX stock is "Strong Buy." The 12-month stock price target is $75.2, which is an increase of 175.46% from the latest price.
News
Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors
WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeu...
Tectonic Therapeutic Transcript: Leerink Global Healthcare Conference 2026
Two clinical programs are advancing: TX45, a long-acting relaxin for pulmonary hypertension, is differentiated by patient selection and dosing, with Phase II results expected in late 2026 or early 2027. TX2100, an anti-angiogenic agent for HHT, shows strong preclinical efficacy and safety, with Phase I data due this year. The proprietary platform supports ongoing pipeline innovation.
Tectonic Therapeutic Transcript: TD Cowen 46th Annual Health Care Conference
The session highlighted progress on two clinical programs targeting major unmet needs in pulmonary hypertension and hereditary hemorrhagic telangiectasia, with key data readouts expected in late 2024 and 2026/2027. Competitive insights and trial design refinements position the pipeline for significant impact.
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
WATERTOWN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeut...
Tectonic Therapeutic Transcript: KOL event
TX2100 is a first-in-class APJ antagonist targeting HHT, aiming to address a major unmet need with a differentiated, pathology-biased anti-angiogenic mechanism. Robust preclinical efficacy and safety data support ongoing clinical trials, with a focus on improving epistaxis and expanding to related disorders.
Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board
WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeut...
Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026
WATERTOWN, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeut...
Tectonic Therapeutic Transcript: Piper Sandler 37th Annual Healthcare Conference
APEX study enrollment is progressing as planned, now focusing on high PVR patients for greater efficacy. No safety concerns have emerged, and the trial is differentiated by its design and molecular construct. Financially, the company is well-funded through Q4 2028.
Tectonic Therapeutic Transcript: Study Result
A single dose of TX45 in PH-FrEF patients was well tolerated and produced significant, sustained improvements in key hemodynamic parameters, including wedge pressure, PVR, and cardiac output, with echo data supporting persistent benefits at day 29. These results support further clinical development, with the APEX phase II trial ongoing and top-line data expected in 2026.
Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF
WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced positive topline results from the Phase 1b Part B acute hemodynamic clinical...
Tectonic Therapeutic Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
TX45, a long-acting relaxin mimetic, is advancing through clinical trials for heart failure and pulmonary hypertension, showing strong efficacy in early studies. The pipeline is expanding to new indications, with additional programs and key data readouts expected through 2026.
Tectonic Therapeutic Transcript: Cantor Global Healthcare Conference 2025
A differentiated relaxin program is advancing with strong phase 1B data in pulmonary hypertension and a focus on stable, well-managed patients. Upcoming data in reduced ejection fraction heart failure and a new program in hereditary hemorrhagic telangiectasia expand the pipeline.
Tectonic Therapeutic to Participate in September Investor Conferences
WATERTOWN, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeut...
Tectonic Therapeutic Joins Russell 3000® Index
WATERTOWN, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeut...
Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025
WATERTOWN, Mass., May 17, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”) today announced the complete results from Part A of the Phase 1b clinical trial of TX45 in pat...
Tectonic Therapeutic Transcript: BofA Securities 2025 Healthcare Conference
The company highlighted its progress in GPCR-targeted biologics, focusing on a long-acting relaxin program for pulmonary hypertension with promising phase I-B results and a large market opportunity. Strong financials and a robust pipeline position it for key milestones in 2025 and 2026.
Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights
WATERTOWN, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeuti...
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
WATERTOWN, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeu...
Tectonic Therapeutic Transcript: Leerink Global Healthcare Conference 2025
TX45 demonstrated strong hemodynamic improvements in phase I-B, targeting a large cpcPH patient group and potentially expanding to HFpEF. The phase II APEX trial is enriched for high PVR patients, with results expected in 2026. Recent financing extends the cash runway past mid-2027.
Tectonic Therapeutic Transcript: TD Cowen 45th Annual Healthcare Conference
A novel biologics platform is advancing TX45, a long-acting Relaxin, for pulmonary hypertension with strong phase 1B data showing significant hemodynamic improvements and a favorable safety profile. The program targets a large, high-need population and is differentiated by its mechanism and patient selection.
Tectonic Announces $185 Million Private Placement
WATERTOWN, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced that it has entered into a securities purchase agreement for a private inve...
Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced positive interim data from the Phase 1b acute hemodynamic clinical trial of ...
Tectonic Therapeutic Transcript: Status Update
Group 2 pulmonary hypertension, especially in HFpEF, remains a major unmet need due to high prevalence and mortality. TX45, a long-acting relaxin analog, aims to address both vascular and cardiac dysfunction, with phase I-B and II trials targeting 15–20% reductions in wedge pressure and PVR as key efficacy markers.
Tectonic Therapeutic to Host KOL Event on the Unmet Need in Group 2 PH-HFpEF and TX45 as a Potential Treatment on Thursday, December 12, 2024
WATERTOWN, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”) a clinical stage biotechnology company focused on the discovery and development of therapeuti...
Tectonic Therapeutic Transcript: Piper Sandler 36th Annual Healthcare Conference
The conference highlighted the compound's unique pharmacology, longer half-life, and strong clinical rationale for Group 2 PH. Key data readouts are expected in 2025, with a robust financial runway and significant market potential.